No introductions necessary: A TCR upstart with deep-pocket backers partners with one of the new players in the hot gene editing field
Affini-T Therapeutics CEO Jak Knowles, M.D., is no stranger to the kind of startups that draw early capital, having once been vice president of venture investments for Bayer’s VC arm, Leaps by Bayer. But now, he’s the one asking for money, and his former employer is ready to dole it out. Led by Vida Ventures […]
The startup, based in Boston and Seattle, will make T cell therapies for infamously tough-to-treat conditions.
Affini-T Therapeutics has formally launched with $175 million in venture capital, one clinical-stage drug licensed from Fred Hutch and two more solid tumor-targeting drugs that should enter the clinic next year.
See the 24-slide pitch deck a new biotech startup just used to raise $175 million to develop the next cancer breakthrough
Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients. First reported by Geek Wire, Affini-T, based in Boston, is harnessing T cell […]